STOCK TITAN
  1. Home
  2. Sec-filings
  3. EDSA
  4. [Form 4] Edesa Biotech, Inc. Insider Trading Activity

Edesa Biotech (EDSA) director receives 19,000 restricted share units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Marshall Patrick reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech director Patrick Marshall received a grant of 19,000 restricted share units at no cost under the company’s 2019 Equity Incentive Compensation Plan. These units vest in equal monthly installments over twelve months starting from the grant date. After this award, he holds 71,666 common shares directly and 465 shares indirectly through Quidnet Inc.

Positive

  • None.

Negative

  • None.
Insider Marshall Patrick
Role null
Type Security Shares Price Value
Grant/Award Common Shares 19,000 $0.00 --
holding Common Shares -- -- --
Holdings After Transaction: Common Shares — 71,666 shares (Direct, null); Common Shares — 465 shares (Indirect, Held by Quidnet Inc.)
Footnotes (1)
  1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. Quidnet Inc. is wholly owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
RSU grant size 19,000 units Restricted share units granted to Patrick Marshall
Grant price $0.00 per share Equity award issued at no cash cost
Vesting schedule 12 months RSUs vest in equal monthly installments from grant date
Direct holdings after grant 71,666 shares Edesa Biotech common shares directly owned by Marshall
Indirect holdings 465 shares Common shares held through Quidnet Inc.
restricted share units financial
"Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
2019 Equity Incentive Compensation Plan financial
"restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
beneficial ownership financial
"shall not be deemed an admission of beneficial ownership of all of the reported shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"for purposes of Section 16 or for any other purpose"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Marshall Patrick
(Last)(First)(Middle)
C/O EDESA BIOTECH INC.
100 SPY COURT
(Street)
MARKHAML3R 5H6
(City)(State)(Zip)
ONTARIO, CANADA
(Country)		2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares05/27/2026A19,000(1)A$0(1)71,666D
Common Shares465IHeld by Quidnet Inc.(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.
2. Quidnet Inc. is wholly owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Peter J. Weiler, Attorney-in-Fact for Patrick Marshall05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Edesa Biotech (EDSA) report for Patrick Marshall?

Edesa Biotech reported that director Patrick Marshall received 19,000 restricted share units as an equity award at no cost. The grant is part of his compensation package under the company’s 2019 Equity Incentive Compensation Plan and vests over twelve months.

How do Patrick Marshall’s new Edesa Biotech restricted share units vest?

The 19,000 restricted share units granted to Patrick Marshall vest in equal proportions over twelve months, beginning on the grant date. This means a fixed portion of the award becomes fully owned each month during the one-year vesting schedule.

How many Edesa Biotech shares does Patrick Marshall hold after this Form 4 filing?

After the reported grant, Patrick Marshall holds 71,666 Edesa Biotech common shares directly and 465 shares indirectly through Quidnet Inc. These positions reflect his direct ownership and a smaller indirect stake associated with an entity he wholly owns.

Was Patrick Marshall’s Edesa Biotech share grant an open-market purchase?

No, the 19,000 Edesa Biotech shares were granted as restricted share units at a price of $0.00 per share. This represents a compensation-related equity award under the company’s 2019 Equity Incentive Compensation Plan, not an open-market stock purchase.

What is Quidnet Inc.’s role in Patrick Marshall’s Edesa Biotech holdings?

Quidnet Inc. holds 465 Edesa Biotech common shares indirectly for Patrick Marshall. The entity is wholly owned by him, and he disclaims beneficial ownership of those securities except to the extent of his pecuniary interest, as disclosed in the filing’s footnote.